We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+0.99%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.03B
AUM Growth
-$7.04M
Cap. Flow
+$4.18M
Cap. Flow %
0.41%
Top 10 Hldgs %
43.95%
Holding
94
New
9
Increased
28
Reduced
9
Closed
24

Top Buys

Rank Stock Value
1
AMAG
AMAG Pharmaceuticals
AMAG
+$20.2M
2
AEGR
Aegerion Pharmaceuticals
AEGR
+$17.1M
3
UAM
Universal American Corp
UAM
+$12.2M
4
RAD
Rite Aid Corporation
RAD
+$11.8M
5
CORI
Corium International, Inc.
CORI
+$10.6M

Top Sells

Rank Stock Value
1
LCI
Lannett Company, Inc.
LCI
+$24.4M
2
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
+$21M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$14.9M
4
OCR
OMNICARE INC
OCR
+$10.4M
5
MOH icon
Molina Healthcare
MOH
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 79.79%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SCTL
51
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$5.38M 0.53%
749,497
+47,047
+7% +$286K
NGNE icon
52
Neurogene
NGNE
$696M
$4.81M 0.47%
25,525
– –
PLXP
53
DELISTED
PLx Pharma Inc. Common Stock
PLXP
$4.61M 0.45%
59,375
+1,900
+3% +$148K
RDHL
54
Redhill Biopharma
RDHL
$3.85M
$4.6M 0.45%
263
– –
AGEN
55
Agenus
AGEN
$249M
$3.8M 0.37%
60,172
+6,420
+12% +$371K
MRTX
56
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.69M 0.36%
184,756
– –
LJPC
57
DELISTED
La Jolla Pharmaceutical Company
LJPC
$3.56M 0.35%
387,721
+87,721
+29% +$800K
FLXN
58
DELISTED
Flexion Therapeutics, Inc.
FLXN
$3.55M 0.35%
263,204
– –
PHIO icon
59
Phio Pharmaceuticals
PHIO
$12.1M
$3.4M 0.33%
2
– –
TRVN
60
DELISTED
Trevena, Inc.
TRVN
$3.39M 0.33%
960
– –
VXRT
61
DELISTED
Vaxart
VXRT
$3.2M 0.31%
102,012
+44,130
+76% +$1.84M
AKTX
62
Akari Therapeutics
AKTX
$15.2M
$2.92M 0.28%
59
– –
ALBO
63
DELISTED
Albireo Pharma Inc
ALBO
$2.87M 0.28%
44,334
– –
CASM
64
DELISTED
CAS Medical Systems, Inc.
CASM
$2.86M 0.28%
1,424,796
– –
ANTH
65
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$2.6M 0.25%
95,791
– –
LPCN icon
66
Lipocine
LPCN
$17.1M
$1.61M 0.16%
+15,561
New +$1.86M
STRR
67
DELISTED
Star Equity Holdings
STRR
$1.18M 0.12%
6,650
– –
INFI
68
CALL
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$443K 0.04%
+1,500
New +$15.6K
TEVA icon
69
PUT
Teva Pharmaceuticals
TEVA
$35.9B
$210K 0.02%
+4,000
New +$204K
HAE icon
70
Haemonetics
HAE
$3.58B
$127K 0.01%
+3,600
New +$120K
AMRN
71
Amarin Corp
AMRN
$284M
– –
-50,000
Closed -$1.81M
INO icon
72
Inovio Pharmaceuticals
INO
$79.8M
– –
-26,042
Closed -$4.16M
MOH icon
73
Molina Healthcare
MOH
$10.3B
– –
-275,000
Closed -$10.3M
OFIX icon
74
Orthofix Medical
OFIX
$455M
– –
-100,000
Closed -$3.02M
OMER icon
75
Omeros
OMER
$709M
– –
-300,000
Closed -$3.62M
1 2
3
4

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q2 2014 Portfolio in Review

As of Q2 2014, Broadfin Capital held 94 positions worth $1.03B, down 0.68% from $1.03B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Broadfin Capital's Q2 2014 filing shows 9 new, 28 increased, 9 reduced and 24 closed positions. Its largest new stake was Rite Aid Corporation: 80,000 shares worth $11.5M. The largest sale was Lannett Company, Inc., an estimated $24.4M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 80% a quarter earlier, followed by Technology.

  • Broadfin Capital's largest Q2 2014 buy was Rite Aid Corporation: 80,000 shares worth $11.5M.
  • Broadfin Capital added most to AMAG Pharmaceuticals in Q2 2014, an estimated $20.2M increase.
  • Broadfin Capital's biggest Q2 2014 reduction was Assertio, cutting an estimated $9.23M.
  • Broadfin Capital fully exited Lannett Company, Inc. in Q2 2014, selling an estimated $24.4M.
  • Broadfin Capital's ten largest holdings make up 44% of its $1.03B portfolio in Q2 2014.
  • Broadfin Capital opened 9 new positions and closed 24 in Q2 2014.
  • Broadfin Capital's portfolio value fell 0.68% quarter-over-quarter to $1.03B.

Based on Broadfin Capital's 13F filing for Q2 2014, filed 14 Aug 2014.